Nicole Liberio1, Haley Robinson1, Melodee Nugent1, Pippa Simpson1, David A Margolis1, Subramaniam Malarkannan1,2,3,4, Carolyn Keever-Taylor2, Monica S Thakar1,4. 1. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin. 2. Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin. 4. Laboratory of Molecular Immunology and Immunotherapy, Blood Research Institute, Blood Center of Wisconsin, Milwaukee, Wisconsin.
Abstract
BACKGROUND: Donor lymphocyte infusion (DLI) is often used to treat leukemic relapse after hematopoietic cell transplantation (HCT). However, the relationship between outcomes and distinct DLI cellular composition has not been previously reported. Additionally, there are limited published data on efficacy in pediatrics. We evaluated whether DLI cellular content and development of graft-versus-host disease (GVHD) impacted disease and influenced overall survival (OS) in children receiving DLI for recurrent leukemia. METHODS: We performed an Institutional Review Board-approved, retrospective study investigating all consecutive DLIs given to patients at the Children's Hospital of Wisconsin between 1980 and 2018. Analyses were conducted using Mann-Whitney, Fisher exact, and chi-square tests. RESULTS: Thirty patients ≤20 years old with hematologic malignancies (myeloid [AML/MDS/CML/JMML], n = 23; lymphoid [ALL], n = 7) received DLI to treat post-transplant relapse. We found no significant difference in OS or development of GVHD based on CD3, CD4, CD8, CD56, or CD19 DLI cellular composition. With a median follow-up of 0.69 (range, 0.04-16.61) years, OS at five years was 32% ± 9%. The lymphoid group had a five-year survival rate at 71% ± 17% compared with the myeloid group at 22% ± 9%, although not statistically significant (P = 0.11). The development of GVHD did not affect OS (P = 0.62). CONCLUSION: Here, we report a single-center, long-term experience of pediatric DLIs. Surprisingly, many children with ALL were able to achieve durable remissions. Although cellular composition did not have a significant effect on GVHD or OS in our small study, engineering DLI products to maximize specific effector cell populations could be one strategy to improve efficacy.
BACKGROUND:Donor lymphocyte infusion (DLI) is often used to treat leukemic relapse after hematopoietic cell transplantation (HCT). However, the relationship between outcomes and distinct DLI cellular composition has not been previously reported. Additionally, there are limited published data on efficacy in pediatrics. We evaluated whether DLI cellular content and development of graft-versus-host disease (GVHD) impacted disease and influenced overall survival (OS) in children receiving DLI for recurrent leukemia. METHODS: We performed an Institutional Review Board-approved, retrospective study investigating all consecutive DLIs given to patients at the Children's Hospital of Wisconsin between 1980 and 2018. Analyses were conducted using Mann-Whitney, Fisher exact, and chi-square tests. RESULTS: Thirty patients ≤20 years old with hematologic malignancies (myeloid [AML/MDS/CML/JMML], n = 23; lymphoid [ALL], n = 7) received DLI to treat post-transplant relapse. We found no significant difference in OS or development of GVHD based on CD3, CD4, CD8, CD56, or CD19 DLI cellular composition. With a median follow-up of 0.69 (range, 0.04-16.61) years, OS at five years was 32% ± 9%. The lymphoid group had a five-year survival rate at 71% ± 17% compared with the myeloid group at 22% ± 9%, although not statistically significant (P = 0.11). The development of GVHD did not affect OS (P = 0.62). CONCLUSION: Here, we report a single-center, long-term experience of pediatric DLIs. Surprisingly, many children with ALL were able to achieve durable remissions. Although cellular composition did not have a significant effect on GVHD or OS in our small study, engineering DLI products to maximize specific effector cell populations could be one strategy to improve efficacy.
Authors: Giovanni F Torelli; Nadia Peragine; Sara Raponi; Daria Pagliara; Maria S De Propris; Antonella Vitale; Alice Bertaina; Walter Barberi; Lorenzo Moretta; Giuseppe Basso; Angela Santoni; Anna Guarini; Franco Locatelli; Robin Foà Journal: Haematologica Date: 2014-03-21 Impact factor: 9.941
Authors: Yi-Bin Chen; Philip L McCarthy; Theresa Hahn; Sarah A Holstein; Masumi Ueda; Nicolaus Kröger; Michael Bishop; Marcos de Lima Journal: Bone Marrow Transplant Date: 2018-07-23 Impact factor: 5.483
Authors: Stefan O Ciurea; Jolie R Schafer; Roland Bassett; Cecele J Denman; Kai Cao; Dana Willis; Gabriela Rondon; Julianne Chen; Doris Soebbing; Indreshpal Kaur; Alison Gulbis; Sairah Ahmed; Katayoun Rezvani; Elizabeth J Shpall; Dean A Lee; Richard E Champlin Journal: Blood Date: 2017-08-23 Impact factor: 22.113
Authors: Carol Ann Huff; Ephraim J Fuchs; B Douglas Smith; Amanda Blackford; Elizabeth Garrett-Mayer; Robert A Brodsky; Ian W Flinn; Richard F Ambinder; Ivan M Borrello; William H Matsui; Georgia B Vogelsang; Constance A Griffin; Leo Luznik; Richard J Jones Journal: Biol Blood Marrow Transplant Date: 2006-04 Impact factor: 5.742
Authors: Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp Journal: N Engl J Med Date: 2018-02-01 Impact factor: 91.245
Authors: Jacob Rozmus; Sima T Bhatt; Nataliya Prokopenko Buxbaum; Geoffrey D E Cuvelier; Amanda M Li; Carrie L Kitko; Kirk R Schultz Journal: Front Pediatr Date: 2022-03-24 Impact factor: 3.418